The medical device maker has completed more than 40 acquisitions in recent years, helping turn it into one of the state’s ...

Boston Scientific will purchase Ajax Health's Cortex and its OptiMap system to guide physicians performing AFib-treating ...

Cortex adds to Boston Scientific’s electrophysiology portfolio amid treatment shifts in the space driven by new pulsed field ...

As Boston Scientific’s pulsed field ablation business continues to grow, the medtech aims to nourish the program with the ...

Boston Scientific expects to complete enrollment in the coming months in the study comparing pulsed field ablation to ...

2001 St. Jude CRT-ICD 1 Epic HF (V-337) 2004 St. Jude ICD 2 Epic +DR (V-239) 2002 Boston Scientific ICD 2 Vitality DS (T125) 2003 Boston Scientific ICD 1 Vitality 2 (T165) 2003 Boston Scientific ...

Boston Scientific (NYSE: BSX) is scheduled to report its Q3 2024 results on Wednesday, October 23. We expect the company to report revenues and earnings slightly below the consensus estimates.

Investors with a lot of money to spend have taken a bearish stance on Boston Scientific (NYSE:BSX). And retail traders should know. We noticed this today when the trades showed up on publicly ...

Marlborough-based Boston Scientific increased its estimated net sales growth for 2024. Meanwhile, Thermo Fisher slightly raised its full-year adjusted earnings per share guidance. Boston ...

The upcoming report from Boston Scientific (BSX) is expected to reveal quarterly earnings of $0.58 per share, indicating an increase of 16% compared to the year-ago period. Analysts forecast ...

Boston Scientific reported 29.2% growth for cardiology products and 11.8% growth in peripheral interventions. MedSurg segment revenues increased 10.3% to $1.48 billion (10.4% operationally and 7.7 ...